Trontell Embodies AHRQ-FDA Co-sponsorship of CERTs
This article was originally published in RPM Report
Executive Summary
The Agency for Healthcare Research and Quality's new head of the CERTs program, Anne Trontell, MD, MPH, embodies the joint interests of AHRQ and the Food & Drug Administration in the research centers-or as some people refer to it, the parent and godparent status of the two agencies to the centers.
You may also be interested in...
CERTs Look to Re-Assert Larger Role in Post-Marketing Surveillance
There is growing pressure on FDA and Congress to create public-private partnerships for enhanced postmarketing surveillance. The Agency for Healthcare Research and Quality already runs an existing network of academic centers that could fit the bill nicely.
Drug Safety Reform: Did FDA Buy Time or Trouble?
FDA's senior management is worried that it may have created a political Frankenstein when it called for an outside review of the agency's role in drug safety decisions by the Institute of Medicine. The agency asked for the study to take the heat out of Congressional efforts to split up safety and efficacy reviews. The committee has shown interest in the arguments to create new publicly-funded centers for post-market trials.
US Price Negotiation Hearing Lays The Groundwork For Future Improvements
The pharma industry is hoping that litigation might end Medicare price negotiation before it begins. But a House hearing also starts the process of developing legislative improvements that might be viable in years to come – starting with trying to restore the lifespan of small molecules.